$ACXP News

ACURX PHARMACEUTICALS INC (NASDAQ:ACXP) Q1 Results Beat Estimates as Pipeline Advances Steadily

Acurx Pharmaceuticals, Inc. (ACXP) Q1 2026 Earnings Call Transcript

Acurx Pharmaceuticals shares are trading lower after the company announced a $7.1 million registered direct offering.

Acurx Pharmaceuticals shares are trading lower after the company announced a $7.1 million registered direct offering.

Acurx Pharmaceuticals Announces $7.1M Registered Direct Offering Of 825,085 Shares At $3.03/Share

New to The Street Announces Episode 741 Airing Tonight on Bloomberg Television at 6:30 PM EST Featuring Canton Networks, Acme Markets, Virtuix Holdings (VTIX), HPB, Jonas & Redman, Acurx Pharmaceuticals (ACXP), and FreeCast (CAST)

Is Acurx Pharmaceuticals (ACXP) Stock Outpacing Its Medical Peers This Year?

Korean Patent Office Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors

Acurx Pharma Granted Korean Patent For DNA Polymerase IIIC Inhibitors Including Compositions‑Of‑Matter, Methods Of Use, And Pharmaceutical Compositions

Acurx Pharmaceuticals Inc (ACXP) Q4 2025 Earnings Call Highlights: Financial Growth and ...

Can Acurx Pharmaceuticals (ACXP) Climb 226.3% to Reach the Level Wall Street Analysts Expect?

Is Acurx Pharmaceuticals (ACXP) Outperforming Other Medical Stocks This Year?

Acurx Pharmaceuticals, Inc. (ACXP) Q4 2025 Earnings Call Transcript

Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business Update

What's Going On With Acurx Pharmaceuticals Stock Today?

Acurx Pharmaceuticals Q4 EPS $(0.73) Beats $(1.65) Estimate

Why Is Acurx Pharmaceuticals Stock Falling Thursday?

Why Is Acurx Pharmaceuticals Stock Up Over 105% Today?

Acurx Pharmaceuticals shares are trading higher after the company announced that it will conduct a new clinical trial in patients with recurrent C. difficile Infection while its program in the broader CDI patient population is ready to advance to Phase 3 international clinical trials.

Acurx Announces New Ibezapolstat Clinical Trial Program in Patients with Recurrent CDI That Has the Potential to Shift the Paradigm of Treatment and Prevention of C. difficile Infection